De-risking Drug Discovery with AI
On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when…
Louis was the Senior Analyst and Editor-in-Chief from 2013 to 2019. He currently collaborates with PharmaBoardroom as external editor. Having directed pharmaceuticals & life science projects across 4 continents, he has published over 30 country reports as well as produced analytical studies on trends in blockchain, Pharma M&A and biotechnology. He has a professional background in consultan more...
On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when…
The AI in Life Sciences Market was valued at USD 902.1 million in 2019 by Mordor Intelligence and is projected to expand at an impressive 20 percent compound annual growth…
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard…
With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a…
PharmaBoardroom’s new InFocus section examines the fast-growing and lucrative global medical cannabis market, touching on investment opportunities, regulatory hurdles, regional hotspots and more. With cannabis and cannabinoid treatments increasingly…
Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease specialist, Jazz pharma has been making tremendous headway in the onco-haematology and…
Many of the world’s mega-rich are increasingly active philanthropists in the healthcare arena and Spain is no exception with Galician billionaire Amancio Ortega Gaona, the 82-year-old owner of clothing empire…
The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones for the maverick South African pharmaceutical outfit Aspen, enabling the company to…
Five of the key emerging trends in the booming global medical cannabis and cannabinoid medicine industries. Increasing Acceptance The reappearance of cannabis as a tool in our therapeutic toolbox…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but…
In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants,…
See our Cookie Privacy Policy Here